Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TT-00420 in Advanced Solid Tumors, Biliary Tract Cancer and Triple-negative Breast Cancer
CTR20212760Phase 2Completed
- Sponsor
- TransThera Biosciences
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tinengotinib in Nonhematologic neoplasms, biliary cancer, triple-negative breast cancer (TNBC) and 9 more (3 arms), sponsored by TransThera Biosciences. Primary endpoints: Safety assessments and Dose-limiting toxicity (DLT). Started Nov 2021; status: completed.
02
Drugs
tinengotinib
03
Conditions
Nonhematologic neoplasmsbiliary cancertriple-negative breast cancer (TNBC)cholangiocarcinoma (CCA)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20212760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212760.